Fate Therapeutics (FATE) Other Non-Current Liabilities (2012 - 2026)
Fate Therapeutics (FATE) posted Other Non-Current Liabilities of $363000.0 for Q1 2026, up 28.27% on a QoQ basis from $283000.0 in Q4 2025, and up 46.96% year-over-year from $247000.0 in Q1 2025.
Fate Therapeutics (FATE) Other Non-Current Liabilities (2012 - 2026) Analysis & Trends
Fate Therapeutics' Other Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $363000.0 for Q1 2026.
- Quarterly Other Non-Current Liabilities rose 46.96% year-over-year to $363000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $363000.0 (up 46.96% YoY) and the FY2025 annual result came in at $283000.0, down 46.3% from the prior year.
- Other Non-Current Liabilities was $363000.0 for Q1 2026 at Fate Therapeutics, up from $283000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $15.8 million in Q1 2022 and bottomed at $247000.0 in Q1 2025.
- A 5-year average of $3.0 million and a median of $1.2 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities tumbled 92.24% — and 2024, when it surged 70.76%.
- Fate Therapeutics' Other Non-Current Liabilities stood at $3.9 million in 2022, then sank by 65.14% to $1.3 million in 2023, then slumped by 60.85% to $527000.0 in 2024, then slumped by 46.3% to $283000.0 in 2025, then advanced by 28.27% to $363000.0 in 2026.
- Business Quant data shows FATE's Other Non-Current Liabilities at $363000.0 in Q1 2026, $283000.0 in Q4 2025, and $410000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Fate Therapeutics | 302.48 Mn | 302.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 363,000.00 |
| Dec 31, 2025 | 283,000.00 |
| Sep 30, 2025 | 410,000.00 |
| Jun 30, 2025 | 320,000.00 |
| Mar 31, 2025 | 247,000.00 |
| Dec 31, 2024 | 527,000.00 |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 1.18 Mn |
| Mar 31, 2024 | 2.74 Mn |
| Dec 31, 2023 | 1.35 Mn |
| Sep 30, 2023 | 701,000.00 |
| Jun 30, 2023 | 1.75 Mn |
| Mar 31, 2023 | 2.14 Mn |
| Dec 31, 2022 | 3.86 Mn |
| Sep 30, 2022 | 9.04 Mn |
| Jun 30, 2022 | 9.93 Mn |
| Mar 31, 2022 | 15.81 Mn |
| Dec 31, 2021 | 24.17 Mn |
| Sep 30, 2021 | 24.63 Mn |
| Jun 30, 2021 | 12.87 Mn |